During the corresponding time, Y Mabs Therapeutics Inc saw a revenue deteriorated by -17.26 % year on year, sequentially revenue fell by -9.76 %. While revenue at the Y Mabs Therapeutics Inc 's corporate clients
Y Mabs Therapeutics Inc's Comment on Sales, Marketing and Customers
The company is developing SADA PRIT technology with two clinical-stage product candidates, GD2-SADA and CD38-SADA, targeting rare oncological diseases. It plans to commercialize future products in the United States independently and pursue strategic collaborations internationally. The company supports hospitals, cancer centers, oncologists, physicians, patients, caregivers, and healthcare providers.
Following FDA approval of DANYELZA, the company established strategic partnerships for commercialization. These include Takeda Israel for Israel, the West Bank, and the Gaza Strip, where the product launched in January 2024; Swixx BioPharma AG for Eastern European territories excluding Russia, following an amendment effective February 2025; SciClone Pharmaceuticals International Ltd. for Greater China (Mainland China, Taiwan, Hong Kong, Macau), where DANYELZA was approved in December 2022 and launched in June 2023, with marketing authorization in Hong Kong expected in the second quarter of 2024; and Adium Pharma S.A. as the exclusive distributor in Latin America, with regulatory approvals obtained in Brazil and Mexico in 2023.
Customers and markets referenced include Adium Pharma S.A., SciClone Pharmaceuticals International Ltd., Swixx BioPharma AG, Takeda Israel, and Takeda Pharmaceutical Company Limited.
Y Mabs Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company is developing SADA PRIT technology with two clinical-stage product candidates, GD2-SADA and CD38-SADA, targeting rare oncological diseases. It plans to commercialize future products in the United States independently and pursue strategic collaborations internationally. The company supports hospitals, cancer centers, oncologists, physicians, patients, caregivers, and healthcare providers.
Following FDA approval of DANYELZA, the company established strategic partnerships for commercialization. These include Takeda Israel for Israel, the West Bank, and the Gaza Strip, where the product launched in January 2024; Swixx BioPharma AG for Eastern European territories excluding Russia, following an amendment effective February 2025; SciClone Pharmaceuticals International Ltd. for Greater China (Mainland China, Taiwan, Hong Kong, Macau), where DANYELZA was approved in December 2022 and launched in June 2023, with marketing authorization in Hong Kong expected in the second quarter of 2024; and Adium Pharma S.A. as the exclusive distributor in Latin America, with regulatory approvals obtained in Brazil and Mexico in 2023.
Customers and markets referenced include Adium Pharma S.A., SciClone Pharmaceuticals International Ltd., Swixx BioPharma AG, Takeda Israel, and Takeda Pharmaceutical Company Limited.
Sources:
Y mabs Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Y mabs Therapeutics inc’s corporate clients.
For your research, we’ve provided 9 tables on Y mabs Therapeutics inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2.65 %